News | August 30, 2023
Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Younger Indians have a 10 times higher rate of heart attack
To address the preventive & primary healthcare delivery gaps in India
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Subscribe To Our Newsletter & Stay Updated
